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Abstract
STAT proteins are cytoplasmic transcription factors that are involved in the regulation of numerous cellular activities
such as cell growth, differentiation, and survival. In this study, we aimed to identify the expression pattern of STAT
genes in imatinib-sensitive and -resistant K562 cells, and further, to reveal the effects of STAT5A siRNA knockdown on
cell growth and apoptosis induction. The XTT cell proliferation assay showed that both sensitive and resistant K562
cells were sensitized to imatinib upon transfection with STAT5A siRNA. Caspase-3 enzyme activity was increased
significantly in both cells. These results may open up new opportunities to overcome chemotherapeutic resistance in
leukemia.
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Introduction
STATs (signal transducers and activator of tran-
scription proteins) are latent cytoplasmic transcrip-
tion factors that, upon activation, carry information
coming from outside the cell into the nucleus.
Extensive studies in mammalian systems have
revealed that STATs consist of seven structural and
functional homolog family members: STAT1,
STAT2, STAT3, STAT4, STAT5A, STAT5B,
and STAT6 [1,2]. STAT activation is normally
achieved by phosphorylation of specific tyrosine
residues, accomplished either by ligand-activated
receptor tyrosine kinases such as the epidermal
growth factor receptor (EGFR) or by receptors
lacking intrinsic tyrosine kinase ability such as
cytokine receptors [3,4]. For the cytokine receptors,
associated Janus kinases (JAKs) first phosphorylate
the receptor itself and then the STATs [5]. Activated
STATs form homo- or heterodimers and translocate
into the nucleus where they bind to GAS (interferon-
g activated sequence) regulatory elements in the
promoters of their target genes and then induce
transcription [6]. They can be involved in the
regulation of several important cellular processes
such as cell growth, differentiation, or cell survival.
Therefore, dysregulation of STATs involved in these
pathways can lead to cellular transformation [7,8].
STATs that usually play a role in the promotion or
suppression of malignant transformations are
STAT1, -3 and, -5. STAT1 exerts tumor suppressive
functions such as induction of apoptosis or growth
arrest, and also contributes to tumor rejection by the
host [9,10]. On the other hand, both STAT5
proteins have been shown to be required for the
development of myeloproliferative diseases [9].
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STAT3 has also been implicated in malignant
transformation and its suppression directs tumor
cells to apoptosis [11,12].
Chronic myeloid leukemia (CML) is a hematolo-
gical cancer characterized by the accumulation of
immature leukemic cells of myeloid origin in the
bone marrow and bloodstream. The main driving
force of this malignancy is the reciprocal transloca-
tion between the q arms of chromosomes 9 and 22,
bringing the BCR (breakpoint cluster region) and
ABL genes together [13,14]. The resultant chromo-
somal structure is referred to as the Philadelphia
chromosome (Ph), and the whole translocation
process results in the expression of the BCR/ABL
fusion protein. Constitutive tyrosine kinase activity of
BCR/ABL causes uncontrolled cell growth, and is
also thought to be responsible for a variety of changes
in normal cellular functions such as differentiation,
adhesion, migration, and apoptotic response [13,15].
Thus, it has become an important target in the
treatment of patients with Ph-positive CML. Im-
atinib was the first chemotherapeutic drug to be
developed against BCR/ABL, and is still widely used
in the first-line treatment of CML. Like other
tyrosine kinases developed afterward, imatinib binds
to the adenosine triphosphate (ATP)-binding do-
main of the fusion protein and prevents the
subsequent phosphorylation of its target proteins,
thereby blocking cell proliferation and inducing
apoptosis [16]. Survival periods of patients with
CML can be substantially prolonged by means of this
drug, but in most cases acquired resistance can affect
the clinical outcome of this therapy. Resistance is
conferred by various mechanisms, one of which
includes mutations in the drug-binding pocket of the
BCR/ABL fusion protein [17,18]. Other mechan-
isms, such as fusion gene amplification (and there-
fore increased expression of the BCR/ABL protein)
and overexpression of cellular efflux proteins, can
diminish the bioavailability of the drug and hence
contribute to resistance [19]. The involvement of
tyrosine kinases other than BCR/ABL might also
be responsible for providing resistance to leukemic
cells [20].
Chemotherapeutic resistance is a major obstacle to
maintaining effective cancer therapies. The adminis-
tration of increased doses of chemotherapeutic drug
in cases where resistant cancerous cells have devel-
oped is not always a good option, because of the
serious side effects these drugs can have. Therefore,
sensitizing these resistant cancerous cells back to
these drugs might be a helpful way of gaining
therapeutic success. Since STATs are implicated in
the regulation of cell growth, manipulation of them
might provide a good opportunity to achieve this
goal. The aim of this study was therefore to
investigate the differential expression pattern of
STAT genes in imatinib-sensitive and -resistant
K562 chronic myeloid leukemia cells, and especially
to reveal the role of STAT5A after siRNA-mediated
gene silencing followed by assessment of cell growth
and apoptosis response.
Methods
Cell lines and culture conditions
Human chronic myeloid leukemia cells, K562, were
obtained from the German Collection of Micro-
organism and Cell Cultures. Cells were grown in
RPMI-1640 medium containing 10% fetal bovine
serum and 1% penicillin–streptomycin; and main-
tained at 378C and in 5% CO2. Imatinib-resistant
K562 cells were developed by exposing them to
increasing concentrations of imatinib for 2 years,
starting with an initial concentration of 50 nM.
Subpopulations of living cells were collected at each
step. Resultant cells that had gained the ability to
grow in the presence of 3 mM imatinib are referred to
as K562-IMA3 cells.
Determination of differentially expressed STAT genes in
imatinib-sensitive and -resistant cells by real-time
RT-PCR
mRNA expression levels of STAT3, STAT5A, and
STAT5B genes were assessed by quantitative real-
time reverse transcriptase-polymerase chain reaction
(Q-PCR) initially, to reveal their differential expres-
sion patterns in imatinib-resistant K562-IMA3 cells.
For this assessment, total RNA was isolated from
both imatinib-sensitive and -resistant cells using the
NucleoSpin1 RNA II Kit (Macherey-Nagel, Easton,
PA, USA) in accordance with the protocol provided
by the manufacturer. Isolated RNAs were reverse
transcribed into cDNAs, and Q-PCR was performed
with gene-specific primers and probes using the
LightCycler1 Fast Start DNA Master HybProbes
Kit and the LightCycler1 2.0 Instrument (Roche
Applied Science, Indianapolis, IN, USA). Glucose-
6-phosphate dehydrogenase (G6PDH) was used as
housekeeping gene in all PCR reactions, and its
amplification product provided both a control for
PCR performance and a reference for quantification
of PCR products. Differential expression values were
calculated from the standard curve obtained; for this
purpose reference standards were used, starting
from 56 106 mRNA copy numbers, decreasing to
56 102 mRNA copy numbers. The efficiency value
calculated from this standard curve was 1.988 with an
error of 0.01, meaning that it could be used reliably in
every PCR reaction. The relative expression level for
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each gene was calculated by dividing the mRNA copy
number of the target gene by the G6PDH mRNA copy
number of the reference gene.
Gene silencing by siRNA transfection
Since STAT5A was the gene whose expression levels
changed most significantly in K562-IMA3 cells, we
focused our interest on this. For its silencing,
HiPerFect Transfection Reagent (Qiagen, Valencia,
CA, USA) was used in combination with cholesterol-
conjugated anti-STAT5A siRNAs (Dharmacon,
Chicago, IL, USA). The cholesterol conjugation
resided at the 50-end of the siRNA sense-strand,
which specifically binds to STAT5A mRNAs. The
reason why cholesterol-modified siRNAs were used
is that they are more stable and, thus, more efficient
in knocking down the target gene. Dulbecco’s
modified Eagle’s medium (DMEM) was used for
preparation of the transfection mixture. Eight hours
after transfection cells were refreshed with new
medium, and imatinib was added to the resistant
cells to a final concentration of 3 mM to maintain
their previous culture conditions. In every experi-
ment, also untreated resistant cells that served as a
control were supplied with the specified concentra-
tion of imatinib. To reach the optimum silencing
effect, cells were incubated totally for 72 h at 378C
and in 5% CO2. Next, appropriate numbers of cells
were collected for the XTT {2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]- 2H-
tetrazolium hydroxide} cell proliferation assay, and
for Q-PCR analysis. Another round of transfection
with new cells was also done for the caspase-3 activity
assay. Again, 16106 cells were allocated for the
verification of silencing through Q-PCR analysis.
Assessment of cellular proliferation by XTT
K562 and K562-IMA3 cells were transfected with
control and STAT5A siRNA and maintained in 96-
well plates with 100 mL growth medium at a
concentration of 26 104 cells/well in the absence or
presence of increased doses of imatinib. After
incubation at 378C and in 5% CO2 for 72 h, XTT
reagent (Cell Proliferation Kit II; Roche) was added
into each well. Absorbance of a sample was measured
by an enzyme-linked immunosorbent assay (ELISA)
reader at 490 nm wavelength of light (Multiskan
Spectrum; Thermo Electron Corporation, Vantaa,
Finland) at the end of 4 h of incubation after adding
XTT reagent. The obtained data were visualized by
plotting cell proliferation curves, and IC50 (drug
concentration that inhibits cell growth by 50%)
values were calculated for both sensitive and resistant
cells.
Measurement of caspase-3 enzyme activity
Activity of the caspase-3 enzyme was assessed at two
different imatinib concentrations for each of the
sensitive and resistant cells. Sensitive cells were treated
with 100 and 200 nM of imatinib, while concentrations
of 5 and 10 mM were selected for K562-IMA3 cells.
Cells were incubated for 72 h at 378C and in 5% CO2
in the presence of the specified concentrations of
imatinib. Assessment of caspase-3 enzyme activity was
done using the Caspase-3 Colorimetric Assay Kit
(BioVision Research Products, Mountain View, CA,
USA) according to the procedure provided by the
manufacturer. In brief, cells were collected by centri-
fugation at 1000g for 10 min and 100 mL of cold lysis
buffer was applied. Following the lysis step, cell debris
were removed by centrifugation at 14 000g for 1 min,
and aliquots of the obtained protein mixture were taken
for measuring the protein amount in extracts by
bicinchoninic acid (BCA) assay. Protein mixtures
were adjusted to equal concentrations according to
results of the BCA assay, and the assessment of
caspase-3 enzyme activity was done by adding 5 mL
of the colorimetric caspase-3 substrate, 20 mL of assay
buffer (56 ), and 50 mL of distilled water to 25 mL of
protein samples in 96-well plates. To enable the
enzymatic reaction, samples were maintained at 378C
for 2 h and sample absorbance was measured at 405
nm wavelength of light via an ELISA reader (Multiskan
Spectrum; Thermo Electron Corporation).
Results
Differential expression patterns of STAT3, -5A, and -5B
in imatinib-sensitive and -resistant K562 cells
Q-PCR analysis revealed that the expression level of
STAT5A was most significantly changed among
STATs examined in K562-IMA3 cells as compared
to K562 cells (Figure 1). Its expression increased by
67%, whereas the expression levels of STAT5B and
STAT3 were increased 56% and 4%, respectively.
These results confirm observations from other
studies, i.e. that activation of STAT3 is not important
in the development of CML, and the present study
now also shows that it does not play a role in the
resistance mechanism developed against imatinib in
CML. In the course of this study, we therefore
mainly focused our interest on STAT5A, since its
expression changed most in imatinib-resistant cells.
STAT5A knockdown in imatinib-sensitive and -resistant
K562 cells
The efficacy of STAT5A knockdown by cholesterol-
conjugated anti-STAT5A siRNAs analyzed by
STAT5A in imatinib resistance and sensitivity 1897
Q-PCR was around 70–80% in imatinib-sensitive
and -resistant K562 cells. In cells used for the XTT
proliferation assay, STAT5A was suppressed by 71%
and 69% for K562 and K562-IMA3, respectively
(Figure 2); also, in cells used for caspase-3 activity
assessment by its expression, STAT5A was sup-
pressed by 80% and 71%, respectively, compared to
control groups.
XTT cell proliferation assay of non-transfected and
siRNA-transfected cells
XTT cell proliferation assays were performed using
different concentrations of imatinib for K562 and
K562-IMA3 cells. This resulted in cell proliferation
curves that enabled the calculation of IC50 values.
For non-transfected K562 and K562-IMA3 cells,
imatinib IC50 values were calculated as 280 nM and
14761 nM, respectively (Figures 3 and 4); on the
other hand, IC50 values for cholesterol-conjugated
anti-STAT5A siRNA-transfected K562 and K562-
IMA3 cells were 248 nM and 3285 nM, respectively
(Figures 3 and 4). Taken together, these results
indicated that silencing of STAT5A had sensitized
both sensitive and resistant K562 cells to imatinib.
siRNA-transfected resistant cells became almost 4.5
times more sensitive to imatinib than their non-
transfected counterparts, while transfected sensitive
cells showed approximately 1.12-fold increased
sensitivity.
Assessment of caspase-3 enzyme activity
Activation of caspase-3 is particularly important for
the execution of apoptosis. For this reason, we
assessed the activation of this enzyme to investigate
the apoptosis induction of cells upon treatment with
imatinib, before and after anti-STAT5A siRNA
transfection. Enhanced apoptosis induction was
concurrent with the suppression of STAT5A expres-
sion in both imatinib-sensitive and -resistant
K562 cells. For K562-IMA3 cells, there were
Figure 1. Differential expression of STAT genes in K562 and K562-IMA3 cells. Expression of each of the genes was normalized to 100% for
K562 cells and then K562-IMA3 data were plotted relative to that normalization. Error bars demonstrate standard deviations and p50.05
was considered as statistically significant.
Figure 2. Expression levels of STAT5A in non-transfected and STAT5A siRNA-transfected cells before proceeding with XTT proliferation
assay and caspase-3 enzyme activity assessment. Non-transfected K562 and K562-IMA3 data were normalized to 100% separately and
expression levels after siRNA transfection are depicted relative to these. Error bars indicate standard deviations of measurements and
p5 0.05 was considered as significant.
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dose-dependent increases in caspase-3 enzyme activ-
ity in non-transfected and siRNA-transfected sam-
ples (Figure 5). Non-transfected K562-IMA3 cells
showed 1.85- and 3.46-fold increases in caspase-3
enzyme activation in the presence of 5 and 10 mM
imatinib, while siRNA-transfected counterparts
showed 11.21- and 20.17-fold increases. These
results are in accordance with the XTT data obtained
for K56-IMA3 cells as noted in the previous section.
Non-transfected sensitive K562 cells also showed
dose-dependent increases in caspase-3 enzyme activ-
ities, which were 2.95- and 3.38-fold in the presence
of 100 and 200 nM imatinib. However, siRNA-
transfected sensitive K562 cells demonstrated an
unusual pattern: they showed a decrease in caspase-3
enzyme activity by 0.83-fold in the presence of 100
nM imatinib, but a 20.18-fold increase in the
presence of 200 nM imatinib (Figure 6).
Discussion
In this study, the effects of STAT5A silencing on
chemotherapeutic cell death and resistance were
investigated. Suppression of STAT5A expression
was achieved by transfection of cholesterol-conju-
gated anti-STAT5A siRNAs into human chronic
myeloid leukemia cells that were either sensitive or
resistant to imatinib, a BCR/ABL tyrosine kinase
inhibitor. Our experimental results have shown that
diminution of STAT5A expression evokes increased
induction of apoptosis and enhanced sensitivity to
imatinib, therefore making it important for leukemic
cell survival.
At the initial stage of our study we found that the
most significant changes in gene expression hap-
pened for STAT5A in imatinib-resistant K562
chronic myeloid leukemia cells, possibly indicating
its importance in this process rather than of STAT3
(since the amount of STAT3 expression was much
less than of STAT5A and STAT5B). Leukemic cells
Figure 4. Effect of imatinib on the growth of STAT5A siRNA-
transfected and non-transfected K562 cells. Error bars indicate
standard deviations in the experiment, and if they are not apparent,
the thickness of the bar is less than the proliferation curve itself. As
in the previous analyses, p50.05 was defined as statistical
significance.
Figure 3. Effect of imatinib on the growth of STAT5A siRNA-
transfected and non-transfected K562-IMA3 cells. Error bars
indicate standard deviations in the experiment, and when not seen,
they are smaller than the proliferation curve itself. Similar to the
previous analyses, p5 0.05 was defined as statistical significance.
Figure 5. Percent changes in caspase-3 enzyme activity in non-transfected and STAT5A siRNA-transfected K562-IMA3 cells. Data were
normalized to 100% for non-transfected and siRNA-transfected results separately for control samples, and data points are depicted relative to
those normalizations. Error bars show standard deviations in the experiment. Values of p50.05 were considered as statistically significant.
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usually develop multiple features to cope with the
stress of chemotherapy, one of which is amplification
of the fusion protein. Our previous studies have
shown that an elevated level of BCR/ABL is an
important factor in conferring chemotherapeutic
resistance to CML cells [17]. There are studies
indicating that BCR/ABL induces activation of
STAT5 [21,22], and from this perspective, our
findings are in accordance with the previous litera-
ture. This situation might be useful in explaining the
difference in chemotherapeutic sensitization of im-
atinib-sensitive and -resistant cells upon siRNA
transfection. Resistant cells became approximately
4.5 times more sensitive, while sensitive cells showed
around 1.12-fold increased sensitivity. If the in-
creased activation of STAT5A is related to the
achievement of resistance, then silencing of STAT5A
would have more profound effects on K562-IMA3
cells than on imatinib-sensitive K562 cells, whose
STAT5A expression remained diminutive compared
to the high expression in resistant cells. These
significant results were obtained when the silencing
efficiency of STAT5A was around 70%. By further
experimentation with increased silencing efficiencies,
these differences might become even higher between
the imatinib-sensitive and -resistant CML groups.
When caspase-3 enzyme activity test results were
examined, generally an imatinib dose-dependent
increase was observed. However, siRNA-transfected
K562 cells showed a relatively different pattern, with a
slight decrease at 100 nM of imatinib and around 20-
fold increase at the next drug concentration, which was
200 nM. This pattern might be attributed to a delayed
response to the drug, but does not seem particularly
important since there was a more than 20-fold increase
at the next concentration. When compared to the 200
nM data, the magnitude of decrease also seemed not
so significant. However, to further investigate whether
such a pattern of decrease occurs before that particular
data point, additonal caspase-3 enzyme activity experi-
ments might be performed, involving smaller drug
concentrations. Imatinib, as part of its mechanism of
action, blocks activity of the BCR/ABL fusion protein
by specifically binding to its ATP-binding domain,
leading to apoptotic cell death by this means.
Increased caspase-3 enzyme activity showed that cells
were still dying through apoptosis in the presence of
imatinib upon transfection with cholesterol-conjugated
anti-STAT5A siRNAs.
These results may have clinical importance, too,
since drug resistance is one of the major problems in
cancer therapy. Through our experiments, we have
shown that resistant CML cells could be sensitized to
obtain more effective chemotherapeutic responses.
One may speculate that the IC50 value of siRNA-
transfected resistant cells is still high (especially when
compared to the IC50 value of sensitive cells), and
therefore this approach is not feasible enough for a
clinical impact. However, the following explanations
might provide answers to these concerns. Our first
explanation involves the efficiencies of transfection
and gene silencing. These results were obtained
when STAT5A expression was silenced around 70–
80%. Silencing with increased efficiency or complete
removal of the gene by homologous recombination
might provide better responses to imatinib in
resistant cells. The second explanation could be
that other STAT family members might physiologi-
cally make up the loss of STAT5A activity. STAT3
and STAT5B are good candidates for such a
mechanism, since they are frequently found to be
overexpressed in various cancers [23,24]. Because of
the high gene homology it shares with STAT5A,
STAT5B may be involved with it in redundant
functions [25], for example reducing the inhibition of
cell growth, similar to STAT5A. It might be
Figure 6. Percent changes in caspase-3 enzyme activity in non-transfected and STAT5A siRNA-transfected K562 cells. Data were
normalized to 100% for non-transfected and siRNA-transfected results separately for control samples, and data points are depicted relative to
those normalizations. Error bars show standard deviations in the experiment. Values of p50.05 were considered as statistically significant.
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interesting to investigate cell growth under the
application of chemotherapy when both STAT5 genes
are simultaneously suppressed. Also, experiments
investigating the silencing effects of STAT genes on
cell growth might be conducted with other chemother-
apeutic agents to obtain detailed information about the
relationship between these genes and multi-drug
resistance. Nevertheless, observing these significant
responses to imatinib after transfection with single
gene-specific siRNAs might provide new opportunities
for dealing with the frequent occurrence of resistance
to chemotherapeutic agents in leukemia.
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